OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Islam on Treatment of Patients With Hodgkin Lymphoma With or Without HIV

April 16th 2023

Jessica Yasmine Islam, PhD, MPH, discusses the treatment of patients with Hodgkin’s lymphoma who do or do not have HIV.

Women in Oncology: The Evolution of Active Mentorship

April 14th 2023

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the differences that can arise between the mentorship strategies of men and women and the importance of finding mentors that help with individual career growth and personal goal accomplishment.

Women in Oncology: Early Career Growth and Institutional Change

April 14th 2023

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss their early career experiences as women in the oncology field.

Dr Ademuyiwa on the Implications of the KEYNOTE-522 Trial in Early-Stage TNBC

April 14th 2023

Foluso Bisi Ademuyiwa, MD, MPH, MSCI, discusses the implications of the phase 3 KEYNOTE-522 trial in high-risk, early-stage triple-negative breast cancer.

Dr Liu on the Activity of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

April 14th 2023

Stephen V. Liu, MD, discusses the activity of trastuzumab deruxtecan in patients with HER2-mutated non–small cell lung cancer.

Dr McGregor on Next Steps For Cabozantinib Plus Atezolizumab in Advanced RCC

April 14th 2023

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Dr Christensen on the Influence of Patient Selection for BCL-2 Inhibitor Treatment in AML

April 14th 2023

Bradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.

Dr Verschraegen on Toxicities Associated with Single-agent vs Doublet Immunotherapy in Melanoma

April 14th 2023

Claire F. Verschraegen, MD, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma.

Dr Fader on Letrozole With or Without Paclitaxel and Carboplatin in Ovarian Serous Carcinoma

April 13th 2023

Amanda Nickles Fader, MD, discusses the randomized, phase 3 NRG-GY019 trial evaluating letrozole with or without paclitaxel and carboplatin in patients with stage II to IV primary low-grade serous carcinoma of the ovary or peritoneum.

Dr Slomovitz on the Classification of Molecular Subtypes to Guide Treatment in Endometrial Cancer

April 13th 2023

Brian M. Slomovitz, MD, discusses the classification of molecular subtypes to guide treatment and care in endometrial cancers.

Dr Lathan on Community-based Cancer Evaluation Services in Underserved Patient Groups

April 13th 2023

Christopher Lathan, MD, MS, MPH, discusses socioeconomical and clinical findings from a clinical outreach program incorporating cancer diagnostic services and patient navigation for patients from traditionally underserved populations.

Dr Cun on Molecular Classification in Endometrioid Endometrial Adenocarcinoma

April 13th 2023

Han T. Cun, MD, MS, discusses the findings from a retrospective comprehensive molecular classification of patients with grade 3 endometrioid endometrial adenocarcinoma.

Dr Alvero on Antitumor Immunological Memory in Ovarian Cancer Models

April 13th 2023

Ayesha Alvero, MD, MSc, discusses findings from a preclinical study investigating the antitumor effects and recurrence prevention abilities of a virus-like vesicle thought to establish immunological memory in mouse models with ovarian cancer.

Dr Randall on the Evaluation of Ganitumab Plus VDC/IE in Newly Diagnosed Metastatic Ewing Sarcoma

April 13th 2023

R. Lor Randall, MD, FACS, discusses the investigation of ganitumab plus standard-of-care interval-compressed chemotherapy in a phase 3 trial for newly diagnosed metastatic Ewing sarcoma.

Dr Godara on the Selection of CAR T-Cell Therapies vs Bispecific Antibodies in R/R Multiple Myeloma

April 13th 2023

Amandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.

Dr Mahtani on Treatment Sequencing in HER2+ Metastatic Breast Cancer

April 12th 2023

Reshma Lillaney Mahtani, DO, discusses available therapies in the first-, second-, and later-line settings in patients with HER2-positive metastatic breast cancer.

Dr González-González on DDR Pathway Inhibition in HER2-low TNBC Breast Cancer Models

April 12th 2023

Adrian González-González discusses findings from a preclinical study of trastuzumab deruxtecan in combination with DNA damage response (DDR) pathway inhibitors in xenograft models derived from patients with HER2-low triple-negative breast cancer.

Dr Deol on CAR T-cell Therapy Selection for Patients With Relapsed/Refractory Myeloma

April 12th 2023

Abhinav Deol, MD, discusses the selection of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.

Dr Graff on the Evaluation of Trastuzumab Deruxtecan in HER2-Zero Breast Cancer

April 12th 2023

Stephanie L. Graff, MD, discusses the evaluation of trastuzumab deruxtecan in patients with HER2-zero metastatic breast cancer in the ongoing, phase 2 DESTINY-Breast06 trial.

Dr Fashemi on the Effect of Entinostat on Olaparib Responsiveness in Mouse HRP Ovarian Cancer Models

April 12th 2023

Bisiayo Fashemi, PhD, discusses how the addition of entinostat to olaparib could help combat PARP inhibitor-resistance in homologous recombination proficient ovarian cancer, as well as the clinical significance of utilizing mouse organoid models to investigate such strategies.